3P Biopharmaceuticals
3P Biopharmaceuticals (3P) is a leading European CDMO specializing in the process development and GMP manufacturing of biologics products using microbial and mammalian expression systems.
3P offers solutions for biologics at all stages of product development: from research and development, all through the preclinical and clinical phases to commercial supply.
During more than 12 years of its performance 3P has worked with more than 50 different recombinant proteins and other biologics. It can support biologics with process and analytics development, DS and DP testing, release and stability, as well as GMP material supply for clinical trials and market.
3P Biopharmaceuticals and SpyBiotech enter into a vaccine contract manufacturing agreement
[No·in, Spain, October 26, 2020]3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has signed a manufacturing agreement withSpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases.
3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder
[Pamplona, July 23th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in the process development and GMP manufacturing of biologics announces Keensight Capital, one of the European leading players in Growth Buyout, specialist in the IT and Healthcare sectors, as its new major investor. The incorporation of this new main...
3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment
The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the bodyís immune system
3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody
[No·in, May 27, 2019] 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody.
Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)
- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
3P Biopharmaceuticals signs partnership agreement with the Australian company Ondek
Pamplona, 14 March 2017. 3P Biopharmaceuticals, a leading European CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Australian company Ondek, a biotechnology company developing natural immune modulatory products, for the production of an innovative immunotherapy based on the Helicobacter pylori organism. The agreement will allow...
Validation batches of the vaccine against equine strangles Strangvac is completed
[No·in, January 27, 2020] 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics has, together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against equine strangles called Strangvac. The validation production batches required for the forthcoming registration application...
Neovacs signs production partnership with 3P Biopharmaceuticals, a leading GMP producer of biological drugs
Paris and Boston, November 23, 2016 - Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced a partnership with 3P Biopharmaceuticals, a leader in the production of biological drugs, for the manufacture of interferon alpha (IFNα). Todayís collaboration follows the recent acquisition of the technology for the...
3P Biopharmaceuticals has hired a new Senior Head of Business Development
Pamplona, 21 October 2016. 3P Biopharmaceuticals is pleased to announce the recent employment of Andrew Carver as its new Senior Head of Business Development. Andrew is a senior executive with more than 30 yearsí experience in the Pharmaceutical, Biotechnology and Life Science industries. Andrew joins 3P Biopharmaceuticals from Fujifilm Diosynth Biotechnologies, a UK based CDMO,...
3P Biopharmaceuticals to hold third 3PBio Forum this month
Pamplona, 1 September 2016. 3PBiopharmaceuticals has selected BIOSPAIN 2016 as the setting for the third edition of 3PBio Forum, a biotechonology form organized annually - and since 2014 -by 3P. The session will take place during the second day of BIOSPAIN, on Thursday, 29 September, from 11.00-12.30 in room D of the BEC (Bilbao Exhibition...
Polígono Industrial Mocholí, Pl. Cein, 1, 31110 Noáin, Navarra
+34 948 34 64 80